EnVVeno Medical's VenoValve: A Cost-Effective Solution for Severe CVI

enVVeno Medical Corporation has announced findings from a health economic study on its VenoValve, suggesting it may offer a cost-effective treatment for severe chronic venous insufficiency (CVI). According to the study, VenoValve could improve health outcomes and reduce healthcare costs significantly, potentially saving up to $5.9 billion annually for around 2.5 million U.S patients.

The study highlighted substantial savings and clinical benefits. It predicts cost savings of $32,442 per patient over five years and an avoidance of 2.2 ulcers per patient. Additionally, it offers a 0.33 quality-adjusted life years improvement. Savings could reach $14,912 for each ulcer avoided.

The cost-effectiveness analysis model, validated through multiple simulations, ensures robust and consistent results. enVVeno has submitted a pre-market authorization for the VenoValve to the FDA, with a decision expected in late 2025.